Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience

Bang,Hyun Jin; Kim,Hyeon-Jong; Lee,Seung Hyuk; Shim,Hyun Jeong; Hwang,Jun Eul; Bae,Woo Kyun; Chung,Ik-Joo; Cho,Sang-Hee

doi:10.3892/ol.2024.14524

Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience

Authors:
- Hyun Jin Bang
- Hyeon-Jong Kim
- Seung Hyuk Lee
- Hyun Jeong Shim
- Jun Eul Hwang
- Woo Kyun Bae
- Ik-Joo Chung
- Sang-Hee Cho
View Affiliations

Affiliations: Division of Hemato‑Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam 58128, Republic of Korea
Published online on: June 21, 2024 https://doi.org/10.3892/ol.2024.14524
Article Number: 391
Copyright: © Bang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of induction chemotherapy (IC) in locally advanced oropharyngeal cancer (OPC) remains debatable, and suitable candidates for de‑escalation treatment in these patients have not been fully identified. Therefore, the present study aimed to identify high‑risk candidates for human papillomavirus (HPV)‑positive OPC by analyzing patients who underwent IC followed by chemoradiotherapy (CRT) to guide optimal treatment strategies. Patients diagnosed with stage III‑IVA OPC and treated with a minimum of two cycles of IC followed by CRT, between 2004 and 2020, were retrospectively reviewed. All the patients were restaged according to the American Joint Committee on Cancer, 8th edition. The overall response rate and survival outcomes associated with clinical factors based on HPV status were analyzed using univariate and multivariate analyses. The present study analyzed 105 patients with a median age of 60 years (range, 40‑76 years). Among 105 patients, 40 (38.1%) were HPV‑negative and 65 (61.9%) HPV‑positive. In all patients, survival outcomes were notably poorer in patients aged ≥60 years (P=0.006) and those who did not achieve complete response post‑CRT (P<0.001), irrespective of the HPV status. The median relative dose intensity of IC was ≥80%, indicating adequate treatment, regardless of age. In contrast to patients with HPV‑negative OPC, age ≥60 years (P=0.011) and T4 stage (P=0.019) emerged as substantial poor prognostic factors for survival outcomes in patients with HPV‑positive OPC. Patients with HPV‑positive OPC were categorized into three groups based on the number of clinical factors at diagnosis (such as age and T4 stage). The progression‑free and overall survival showed significant stratification across each group as the number of high‑risk factors increased despite IC and CRT. The findings indicated that patients with these high‑risk factors require a cautious therapeutic strategy even when they are diagnosed with HPV‑positive OPC, and the role of combined modality, including IC, will need to be investigated in a randomized trial to be routinely incorporated into clinical practice.

View Figures

View References

1	Siegel RL, Giaquinto AN and Jemal A: Cancer statics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI
2	Korea National Cancer CenterNational Cancer Registration Project Annual Report (2020 Cancer Registration Statistics), . https://ncc.re.kr/cancerStatsView.ncc?bbsnum=638&searchKey=total&searchValue=&pageNum=1May 19–2023(In Korean).
3	Faraji F, Rettig EM, Tsai HL, El Asmar M, Fung N, Eisele DW and Fakhry C: The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer. 125:761–769. 2019. View Article : Google Scholar : PubMed/NCBI
4	Kang EJ, Lee YG, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Kim HJ, Lee KW, Kim MK, et al: Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). Korean J Intern Med. 37:190–200. 2022. View Article : Google Scholar : PubMed/NCBI
5	Lechner M, Liu J, Masterson L and Fenton TR: HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 19:306–327. 2022. View Article : Google Scholar : PubMed/NCBI
6	Rettig EM, Fakhry C, Khararjian A and Westra WH: Age profile of patients with oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 144:538–539. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
8	Cao X, Hou J, An Q, Assaraf YG and Wang X: Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 49:1006712020. View Article : Google Scholar : PubMed/NCBI
9	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition. Springer; New York, NY: 2017
10	Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, et al: Head and Neck Cancers, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024.
11	Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, et al: E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. J Clin Oncol. 35:490–497. 2017. View Article : Google Scholar : PubMed/NCBI
12	Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, et al: OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 30:16732019. View Article : Google Scholar : PubMed/NCBI
13	Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, Riaz N, Tsai CJ, Kriplani A, Hung TKW, et al: Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin. 73:164–197. 2023. View Article : Google Scholar : PubMed/NCBI
14	Kim MJ, Ki MS, Kim K, Shim HJ, Hwang JE, Bae WK, Chung IJ, Lee DH, Lee JK, Yoon TM, et al: Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status. BMC Cancer. 14:8242014. View Article : Google Scholar : PubMed/NCBI
15	World Health Organization and Regional Office for the Western Pacific, . The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia; Sydney: pp. 182000, https://iris.who.int/handle/10665/206936May 19–2023
16	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chow LQM: Head and Neck Cancer. N Engl J Med. 382:60–72. 2020. View Article : Google Scholar : PubMed/NCBI
18	Chen SY, Massa S, Mazul AL, Kallogjeri D, Yaeger L, Jackson RS, Zevallos J and Pipkorn P: The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A systemic review. Am J Otolaryngol. 41:1025922020. View Article : Google Scholar : PubMed/NCBI
19	Lai YH, Su CC, Wu SY, Hsueh WT, Wu YH, Chen HHW, Hsiao JR, Liu CH and Tsai YS: Impact of alcohol and smoking on outcomes of HPV-related oropharyngeal cancer. J Clin Med. 11:65102022. View Article : Google Scholar : PubMed/NCBI
20	Ferrari D, Ghi MG, Franzese C, Codeca C, Gau M and Fayette J: The slippery role of induction chemotherapy in head and neck cancer: Myth and reality. Front Oncol. 10:72020. View Article : Google Scholar : PubMed/NCBI
21	Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, et al: Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 32:2735–2743. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, et al: Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial. Ann Oncol. 28:2206–2212. 2017. View Article : Google Scholar : PubMed/NCBI
23	Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013. View Article : Google Scholar : PubMed/NCBI
24	Abdelmeguid AS, Teeramatwanich W, Roberts DB, Amit M, Ferraroto R, Glisson BS, Kupferman ME, Su SY, Phan J, Garden AS, et al: Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer. 127:1788–1795. 2021. View Article : Google Scholar : PubMed/NCBI
25	Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C and Licitra L: Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Ann Oncol. 25:462–466. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Kim HJ, Lee KW, Kim MK, et al: Induction chemotherapy as a prognostication index and guidance for treatment of locally advanced head and neck squamous cell carcinoma: The concept of chemo-selection (KCSG HN13-01). Cancer Res Treat. 54:109–117. 2022. View Article : Google Scholar : PubMed/NCBI
27	Zhang Q, Xu T, Shen C, Qian W, Ying H, He X, Wang Y, Ji Q, Hu C, Zhou X and Lu X: Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer. Cancer Med. 12:9175–9185. 2023. View Article : Google Scholar : PubMed/NCBI
28	Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, et al: Poor prognostic factors in human papillomavirus-positive head and neck cancer: Who might not be candidates for de-escalation treatment? Korean J Intern Med. 34:1313–1323. 2019. View Article : Google Scholar : PubMed/NCBI
29	Broughman JR, Xiong DD, Moeller BJ, Contrera KJ, Prendes BL, Lamarre ED, Ku JA, Burkey BB, Woody NM, Joshi NP, et al: Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis. Cancer. 126:2784–2790. 2020. View Article : Google Scholar : PubMed/NCBI
30	Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM III, Barrett WL, Thorstad WL, Jones CU, et al: Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. J Clin Oncol. 35:4057–4065. 2017. View Article : Google Scholar : PubMed/NCBI
31	Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, Ringash J, Bayley A, Kim J, Hope A, et al: Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 33:836–845. 2015. View Article : Google Scholar : PubMed/NCBI
32	Chatsirisupachai K, Lagger C and de Magalhaes JP: Age-associated differences in the cancer molecular landscape. Trends Cancer. 8:962–971. 2022. View Article : Google Scholar : PubMed/NCBI
33	de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, et al: Effects of tobacco smoking on the tumor immune microenvironment in head and neck squamous cell carcinoma. Clin Cancer Res. 26:1474–1485. 2020. View Article : Google Scholar : PubMed/NCBI
34	Khwaja SS, Baker C, Haynes W, Spencer CR, Gay H, Thorstad W, Adkins DR, Nussenbaum B, Chernock RD, Lewis JS Jr and Wang X: High E6 gene expression predicts for distant metastasis and poor survival in patients with HPV-positive oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 95:1132–1141. 2016. View Article : Google Scholar : PubMed/NCBI
35	Flon CH, Haeggblom L, Holzhauser S, Kostopoulou ON, Zupancic M, Dalianis T, Munck-Wikland E, Marklund L and Näsman A: High levels of FGF11 correlate with poor survival in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. Cancers (Basel). 15:19542023. View Article : Google Scholar : PubMed/NCBI
36	de Bakker T, Journe F, Descamps G, Saussez S, Dragan T, Ghanem G, Krayem M and Van Gestel D: Restoring p53 function in head and neck squamous cell carcinoma to improve treatments. Front Oncol. 11:7999932021. View Article : Google Scholar : PubMed/NCBI
37	Dogan S, Xu B, Middha S, Vanderbilt CM, Bowman AS, Migliacci J, Morris LGT, Seshan VE and Ganly I: Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. Int J Cancer. 145:3152–3162. 2019. View Article : Google Scholar : PubMed/NCBI